DE1695354B1 - Verfahren zur Herstellung einer Pyridoxin-Glyoxylsaeure-Additionsverbindung - Google Patents
Verfahren zur Herstellung einer Pyridoxin-Glyoxylsaeure-AdditionsverbindungInfo
- Publication number
- DE1695354B1 DE1695354B1 DE19671695354 DE1695354A DE1695354B1 DE 1695354 B1 DE1695354 B1 DE 1695354B1 DE 19671695354 DE19671695354 DE 19671695354 DE 1695354 A DE1695354 A DE 1695354A DE 1695354 B1 DE1695354 B1 DE 1695354B1
- Authority
- DE
- Germany
- Prior art keywords
- pyridoxine
- glyoxylic acid
- effect
- oxygen
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims description 6
- -1 pyridoxine-glyoxylic acid Chemical compound 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 4
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 32
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 27
- 229940011671 vitamin b6 Drugs 0.000 claims description 13
- 235000008160 pyridoxine Nutrition 0.000 claims description 12
- 239000011677 pyridoxine Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 206010002660 Anoxia Diseases 0.000 description 11
- 241000976983 Anoxia Species 0.000 description 11
- 206010021143 Hypoxia Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000007953 anoxia Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000000496 anti-anoxic effect Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- WOTCTOFEBNHWND-UHFFFAOYSA-M potassium;oxaldehydate Chemical compound [K+].[O-]C(=O)C=O WOTCTOFEBNHWND-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IZMRUZYKDJYBTG-UHFFFAOYSA-N 2-hydroxy-2-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]acetic acid Chemical compound CC1=NC=C(COC(O)C(O)=O)C(CO)=C1O IZMRUZYKDJYBTG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 230000004098 cellular respiration Effects 0.000 description 2
- 230000002566 clonic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000004682 monohydrates Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- BAJPLKFQQKGMGT-UHFFFAOYSA-N 2-hydroxy-2-methoxyacetic acid Chemical compound COC(O)C(O)=O BAJPLKFQQKGMGT-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KFVUXNKQQOUCAH-UHFFFAOYSA-N butan-1-ol;propan-2-ol Chemical compound CC(C)O.CCCCO KFVUXNKQQOUCAH-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- QXKIIRAOFHLZMD-XCVCLJGOSA-N chembl3277911 Chemical compound CC1=NC=C(CO)C(\C=N\O)=C1O QXKIIRAOFHLZMD-XCVCLJGOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical class CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BTNMPGBKDVTSJY-UHFFFAOYSA-M keto-phenylpyruvate Chemical compound [O-]C(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- C07D213/67—2-Methyl-3-hydroxy-4,5-bis(hydroxy-methyl)pyridine, i.e. pyridoxine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR44607A FR4970M (enExample) | 1966-01-03 | 1966-01-03 | |
| FR87172 | 1966-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1695354B1 true DE1695354B1 (de) | 1971-10-14 |
Family
ID=26167914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19671695354 Pending DE1695354B1 (de) | 1966-01-03 | 1967-01-02 | Verfahren zur Herstellung einer Pyridoxin-Glyoxylsaeure-Additionsverbindung |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE691821A (enExample) |
| DE (1) | DE1695354B1 (enExample) |
| ES (1) | ES335167A1 (enExample) |
| GB (1) | GB1109539A (enExample) |
-
1966
- 1966-12-27 BE BE691821D patent/BE691821A/xx not_active IP Right Cessation
- 1966-12-29 GB GB5813166A patent/GB1109539A/en not_active Expired
-
1967
- 1967-01-02 ES ES0335167A patent/ES335167A1/es not_active Expired
- 1967-01-02 DE DE19671695354 patent/DE1695354B1/de active Pending
Non-Patent Citations (1)
| Title |
|---|
| None * |
Also Published As
| Publication number | Publication date |
|---|---|
| BE691821A (enExample) | 1967-05-29 |
| GB1109539A (en) | 1968-04-10 |
| ES335167A1 (es) | 1967-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69317494T2 (de) | Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten | |
| DE69909794T2 (de) | Verwendung eines dipeptids für wiederherstellungsprozesse | |
| DE1670827C3 (de) | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin | |
| DE3120460C2 (enExample) | ||
| DE69533940T2 (de) | Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren | |
| DE2332840A1 (de) | Alpha-sulfobenzylpenicillindiaminsalze und verfahren zu ihrer herstellung | |
| DE1795792A1 (de) | Die serumlipoidkonzentration vermindernde arzneimittel | |
| DE3424781C2 (de) | Verwendung von L-Carnosin zur Tumorbehandlung | |
| DD202561A5 (de) | Verfahren zur Herstellung von Salzen von Naphthyridin- und Chinolin-verbindungen | |
| DE1958226A1 (de) | Pyridoxin-alpha-ketoglutarat | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE2716402A1 (de) | 7-(2,3-dihydroxypropyl)-1,3-di-n- propylxanthin, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel | |
| EP0007597B1 (de) | N-Niedrigalkylglycinamide und Sarkosinanhydrid sowie in Kombination mit bekannten tumorhemmenden Verbindungen vorliegendes Sarkosin zur Anwendung bei der Heilung von Tumoren sowie dieselben enthaltendes Mittel und Verfahren zu dessen Herstellung | |
| CH630901A5 (de) | Verfahren zur herstellung neuer 1-nitro-9-aminoalkylaminoakridine oder deren salze und gemaess diesem verfahren hergestellte 1-nitro-9-aminoalkylaminoakridine oder deren salze. | |
| DE1965431A1 (de) | Inosin-Komplexverbindungen | |
| DE68905406T2 (de) | Chinolin-verbindung. | |
| DE1695354C (de) | Verfahren zur Herstellung einer Pyridoxin-Glyoxylsäure-Additionsverbindung | |
| DE2451360A1 (de) | 9-hydroxyellipticin, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen | |
| EP0817623A1 (de) | Arzneistoffe zur selektiven bekämpfung von tumorgewebe | |
| DE2755016C2 (enExample) | ||
| DE1936723C2 (de) | Salze von Chinarindenalkoloiden und Verfahren zu ihrer Herstellung | |
| DE1518057B2 (de) | Injizierbares adrenocorticotropes hormonpraeparat mit prolongierter acthaktivitaet | |
| DE2920247C2 (de) | Verwendung einer Nitrofuryl-vinylen-thiazol-N-oxid-Verbindung zur Herstellung von Antitumormitteln | |
| DE2059620C3 (de) | 2-(alpha-(p-Chlorphenoxy)-isobutyryl)aminoäthansulfonsäure, ihre physiologisch verträglichen Salze, Verfahren zur Herstellung dieser Verbindungen und pharmakologisch wirksame Zubereitungen derselben | |
| DE2521905C2 (de) | Arzneimittel zur cerebralen Durchblutungsförderung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E77 | Valid patent as to the heymanns-index 1977 | ||
| EGA | New person/name/address of the applicant |